B. Tweedy, Ch. Browne
Tweedy, Browne Co All Funds (US)
Tweedy, Browne Co All Funds (US) Bristol-Myers Squibb Company stake
total: 185
Tweedy, Browne Co All Funds (US) BMY trades
- Total transactions:
- 5
- New positions:
- 1
- Added:
- 4
- Held since:
- 2025 Q2
- Held for:
- 5 quarters
- Latest activity:
- 2026 Q2
According to 2026 Q2 report, Tweedy, Browne Co All Funds (US) holds 37,570 Bristol-Myers Squibb Company (BMY) shares with a market value of roughly $2.16M accounting for 0.16% of the overall portfolio. To date, the estimated cost basis is nearly $53.55 for "buy" trades. Tweedy, Browne Co All Funds (US) first purchased BMY in 2025 Q2, initially acquiring 7,184 shares. Since the initial investment in Bristol-Myers Squibb Company (BMY), Tweedy, Browne Co All Funds (US) has made 4 more transactions.
When did Tweedy, Browne Co All Funds (US) buy Bristol-Myers Squibb Company (BMY)?
Tweedy, Browne Co All Funds (US) first invested in Bristol-Myers Squibb Company (BMY) in 2025 Q2 at the reported quarter-end price of $46.29 per share.
What's the cost basis of Tweedy, Browne Co All Funds (US)'s BMY stake?
The estimated cost basis for Bristol-Myers Squibb Company (BMY) stake is around $53.55 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $53.54
Tweedy, Browne Co All Funds (US)'s historical trades in Bristol-Myers Squibb Company
5 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q2
|
0.16%
|
37,570
|
$57.62
|
$2,164,783
|
+43.63% (+11,412)
|
+0.05%
|
|
2026 Q1
|
0.13%
|
26,158
|
$60.65
|
$1,586,483
|
+55.31% (+9,316)
|
+0.04%
|
|
2025 Q4
|
0.07%
|
16,842
|
$53.94
|
$908,457
|
+16.42% (+2,376)
|
+0.01%
|
|
2025 Q3
|
0.06%
|
14,466
|
$45.10
|
$652,417
|
+101.36% (+7,282)
|
+0.03%
|
|
2025 Q2
|
0.03%
|
7,184
|
$46.29
|
$332,547
|
new
|
+0.03%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.